Indian Journal of Clinical and Experimental Ophthalmology

Print ISSN: 2395-1443

Online ISSN: 2395-1451

CODEN : IJCEKF

Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfil our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free access (Open Access) to its content, which is likely to attract more readers and citations of articles published in IJCEO. Manuscripts must be prepared in more...

  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 109

PDF Downloaded: 42


Get Permission Gajashree S, Guliani, Abrol, Vemparala, and Guliani: The effect of travoprost on subfoveal choroidal thickness in primary open angle glaucoma


Introduction

Glaucoma is a neurodegenerative disease resulting from the loss of retinal ganglion cells due to multifactorial etiology.1 In few patients glaucomatous progression occurs even after the target intraocular pressure is maintained, this enlightens the importance of factors independent of intraocular pressure responsible for glaucoma progressions like ocular blood flow abnormalities, vascular dysregulation, and genetic predisposition.2, 3, 4 Histopathological evaluation of choroid in POAG (Primary open angle glaucoma) patients showed loss of both chorio-capillaries and large vessel layer. 5, 6 The choroid has the highest blood flow per unit tissue body weight and it supplies optic nerve head and outer retina.7 Therefore measuring choroidal thickness using OCT(optical coherence tomography) will indicate the perfusion status of ONH (Optic nerve head).8, 9 Aim of our study was to highlight the role of choroid in POAG.

The choroidal thickness, a sign of ocular blood flow can be altered by prostaglandin analogues.8 The aim of Modern glaucoma therapy is not only to reduce the intraocular pressure but also to increase the optic nerve head perfusion.10 Evidences reported Prostaglandin analogue increases ONH perfusion in addition to reducing IOP (intra ocular pressure). Travoprost (0.004%), a synthetic prostaglandin (PG-F2 alpha) analogue increases both uveoscleral out flow as well as trabecular meshwork outflow.11 Travoprost being lipophilic and because of its higher affinity for FP receptors is ten times more potent than latanoprost. Travoprost and latanoprost increase the pulsatile ocular blood flow but long term effect seen with travoprost.10, 12, 13 Travoprost has a better side effect profile compared to latanoprost and Bimatoprost. According to best of our knowledge no previous studies assessed the effect of topical travoprost therapy on choroidal thickness. Hence, this study was done to analyse the effect of travoprost on subfoveal choroidal thickness.

Materials and Methods

This Prospective study was carried out at a tertiary care centre, New Delhi, India. Fourty one eyes of treatment naive primary open-angle glaucoma were enrolled in this study after the approval from institutional ethical committee. This study was done over the period of 18 months. The Patients diagnosed with any other type of glaucoma except POAG, in need of more than one anti-Glaucoma drug, Ocular pathologies such as cataract, diabetic retinopathy, hypertensive retinopathy, age-related macular degeneration, central serous retinopathy, allergy to travoprost and hyperopia/ myopia more than +/-6D were excluded in this study. A preliminary screening assessment & examination was done on patients such as BCVA by log MAR chart, refraction, IOP by Goldman applanation tonometry, slit-lamp bio microscopy, Gonioscopy was done by Goldman 2 mirror lens using slit lamp and was graded by Shaffer’s grading, Visual field analysis by Humphrey visual field analyser(HVF 30-2), OCT- RNFL analysis, Fundus examination by 90D and Sub-foveal choroidal thickness measured by SD-OCT(EDI mode) at first visit and at 3 months post treatment.

The subfoveal choroidal thickness was measured by spectral-domain OCT (Spectralis/Heidelberg version 1.9.10.0). The patient was positioned properly in front of the machine without dilating the pupil and a horizontal line scan passing over the fovea was taken for analysis. (Figure 1 ). All OCT(EDI) was done between 9 AM to 12 PM to avoid the influence of diurnal variation on choroidal thickness. The choroidal thickness was measured at the subfoveal level from hyperreflective retinal pigment epithelial layer to hypo reflective sclerochoroidal interface. 14 The SFCT (subfoveal choroidal thickness) was measured at first visit before initiation of treatment with topical travoprost and again at 3 months post treatment.

Figure 1

SD-OCT (EDI) scan showing measurement of choroidal thickness at subfoveal level

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/f84ceb27-4507-4dbc-b39d-ed18509cfd18/image/6d7e4bd9-c3fc-49ba-8e0b-568fe659ac75-uimage.png

Statistical analysis

The subfoveal choroidal thickness and IOP before starting travoprost and after 3 months of travoprost was done using Wilcoxon signed rank test. To account for potential skewness in the data distribution both mean and median are reported.

Results

In our study, 41 eyes of POAG patients (25 males and 16 males) were taken. The average age of the study population was 54±9 years. 41% of study population had BCVA of log MAR 0.0, 39% of them had log MAR 0.1 and 20% of them had log MAR 0.2. (Table 1)

Table 1

Descriptive statistics of best-corrected visual acuity of study subjects

Visual Acuity

Number of Cases

Percentage

Log MAR 0.0

17

41%

Log MAR 0.1

16

39%

Log MAR 0.2

8

20%

Total

41

100%

The mean value of IOP at the first visit was 23.56 ± 3.30 mm of Hg and the mean value of IOP after travoprost therapy was 17 ±3.9 mm of Hg.(Table 2) The average IOP reduction was 5.8 ± 2.1 mm of Hg with median value of 6 mm of Hg which was clinically significant (P value <0.001). The IOP is significantly reduced after travoprost therapy in all age groups but the maximum IOP reduction was 7 mm of Hg in 31 to 40 years.(Table 3)

Table 2

Comparison of IOP at first visit and after 3 months

Mean ± SD

Min - Max

Median (IQR)

IOP first visit

23.56 ± 3.30

18 - 30

24 (22 - 26)

IOP after 3 months

17.52 ± 4.85

0 - 26

18 (16 - 20)

Difference in IOP (first visit-3 months)

5.76 ± 2.10

2 - 10

6 (4 - 8)

Difference between IOP %

24.78% ± 10.12%

8.3% - 45.5%

23.07% (16.66% - 32.05%)

p value

<0.001**

Table 3

Distribution of IOP in various age groups at the first visit and after 3 months of travoprost therapy

Age group

IOP(pre-treatment in mm of Hg)

IOP(post-treatment in mm of Hg)

Mean difference in IOP

31 to 40

25.3±3.7

18.3±3.3

7

41 to 50

24.2±2.3

19.2±1.6

5

51 to 60

22.5±3.3

17.3±4.4

5.2

61 to 70

23.6±3.3

17.6±5

5.7

The mean choroidal thickness noted at first visit was 296.73 µm and post treatment was 311.6 µm.(Table 4) The average change in choroidal thickness in this study was 15.85 µm with median value of 8 µm which was clinically significant value<0.001). In our study, an increase in choroidal thickness was noted in all age groups but a significant difference was found in 31 to 40 years of age group.(Table 5)

Table 4

Comparison of choroidal thickness at the first visit and after 3 months

Mean ± SD

Min - Max

Median (IQR)

CT at first visit

296.73 ± 28.07

243 - 370

295 (283 - 312.5)

CT at 3 month

311.56 ± 33.38

246 - 373

318 (289.5 - 343)

Difference in CT (first visit-3 months)

15.85 ± 14.02

2 - 52

8 (3 - 30)

Difference between CT %

5.29% ± 4.65%

0.6% - 17.4%

2.85% (1.08% - 9.38%)

p value

<0.001**

Table 5

Comparison of choroidal thickness at various age groups before and after travoprost

Age group

Choroidal thickness (pre-treatment in Micrometre)

Choroidal thickness (post-treatment in (Micrometre)

Mean choroidal thickness difference in (Micrometre)

31 to 40

308.3±12.1

336.6±14.3

28.3

41 to 50

315.1±26.9

332.2±24.4

17.5

51 to 60

290.8±26

300.7±30.5

11.3

61 to 70

279.2±23.6

291.2±31.2

12

Discussion

Primary open-angle glaucoma is defined as raised IOP more than 21 mm of Hg, characteristic glaucomatous optic disc changes, and visual field changes corresponding to retinal nerve fiber defects with open angles. Vascular etiology plays an important role in understanding the pathophysiology of open-angle glaucoma. Majority of ONH perfusion is contributed by choroidal circulation (90%) and 10% by retinal circulation.10, 15 The role of choroid in open-angle glaucoma is of increasing interest in recent times. Various mechanisms for increase in choroidal thickness following prostaglandin analogue therapy such as vascular permeability, proinflammatory effect, increase in the blood flow velocity as well as ocular perfusion pressure, decrease in the resistive index of central retinal artery and ophthalmic artery.16 Among the above mentioned effects of prostaglandin analogues, travoprost has better long term effect than latanoprost and bimatoprost.10, 12, 13

We evaluated the SFCT using EDI mode by SD- OCT to analyse the choroidal thickness which is an indirect measure of ocular perfusion meanwhile some studies have used doppler ultrasound, laser velocimetry and assessment of ocular pulse amplitude to evaluate choroidal thickness which is difficult and time consuming.10, 13, 17 Therefore measuring SFCT by SD-OCT was a better alternative to doppler ultrasound and laser velocimetry.

A study by Osama stated that the mean age group of POAG patients were 54.4± 9 years.18 According to a study done in south India by Vijaya et al, the mean age of POAG patients was 58.4 years where they had included patients more than 40 years of age.19 In our study the average age of the study population was 54±9 years. Denis P et al concluded that the mean IOP reduction by travoprost was 6.5 to 9 mm of Hg. 12 In another study Ozlem et al compared the effect of travoprost, latanoprost, bimatoprost on IOP. 13 After 6 months of the treatment trial, statistically significant IOP reduction was found in all three prostaglandin analogues groups (P<0.0001). Likewise in our study the mean IOP reduction was 5.7+2.3 mm of Hg after 3 months of travoprost therapy which is comparable to the above mentioned studies.

The mean difference in choroidal thickness between pre-treatment and post-treatment was found to be 15.85 ±15.1 µm with (p-value< 0.00) which was statistically significant. A study by Bayraktar et al used all antiglaucoma medications (prostaglandin analogues, carbonic anhydrase inhibitors, beta blockers and alpha agonists) as well as fixed drug combination and concluded that SFCT was higher in the treatment group.9 Duru et al20 in 2019, assessed the effect of latanoprost on SFCT by SD-OCT (EDI) and found significant increase in SFCT after 3 months of latanoprost therapy.20 Akyol et al. compared the choroidal thickness after using topical bimatoprost, brinzolamide and timolol in POAG patients and he observed significant increase in choroidal thickness with bimatoprost therapy compared to brinzolamide and timolol.8 Based on these studies, its proven that prostaglandin analogues increases the choroidal perfusion and thereby act as neuroprotective agents.

A study by Sahinoglue et al evaluated the effect of latanoprost on choroidal thickness after 1 month of therapy, this study did not show the increase in SFCT. 21 Artunay et al reported a case of Central serous chorioretinopathy after one month of starting latanoprost therapy for glaucoma.22 The possible reason could be increased choroidal permeability. Choroidal permeability being the common mechanism shared by both increase in choroidal thickness as well as development of central serous retinopathy. In view of avoiding side effect associated with latanoprost, travoprost is better option with similar action on choroidal system. Travoprost, being one of the first line drug in the management of POAG has a capability of reducing IOP as well as increases the ONH perfusion. Our study found that Travoprost has the tendency for significant increase choroidal thickness.

Conclusion

The current study showed a statistically significant increase in choroidal thickness and IOP reduction after 3 months of travoprost therapy. Because of the influence of travoprost on vascular supply, acts as neuroprotective agents thus fulfils the modern aim of glaucoma therapy. Additional large sample studies need to conclude this effect.

Source of Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflicts of Interest

None.

Authors Contribution

Dr Gajashree S: Conceptualization, Formal analysis, Writing - original draft preparation. Dr Neha Chawla: Methodology, Data Curation. Dr Sangeeta Abrol/ Dr Rajshekhar Vemparala/ Dr Brahm Prakash Guliani: Writing- review & editing, supervision.

References

1 

A Ahmad S Ahmad S Zulfequar K Najam A Mohammad A Yasir Prevalence and Associated Risk Factors of Glaucoma in Aligarh, India - A population based studyDelhi J Ophthalmol20203113140

2 

JC Mwanza JT Hochberg MR Banitt WJ Feuer DL Budenz Lack of association between glaucoma and macular choroidal thickness measured with enhanced depth-imaging optical coherence tomographyInvest Ophthalmol Vis Sci201152634305

3 

L Quaranta I Riva A Katsanos I Floriani M Centofanti AGP Katsanos Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressureClin Ophthalmol2015963343

4 

RP Maurya Is glaucoma a genetic disordersIndian J Clin Exp Ophthalmol2016231678

5 

CW Spraul GE Lang GK Lang HE Grossniklaus Morphometric changes of the choriocapillaris and the choroidal vasculature in eyes with advanced glaucomatous changesVision Res200242792332

6 

ZQ Yin VTJ Millar P Beaumont S Sarks Widespread choroidal insufficiency in primary open-angle glaucomaJ Glaucoma1997612332

7 

H Kojima K Hirooka E Nitta S Sonoda T Sakamoto Y Kiuchi Assessment of primary open-angle glaucoma peripapillary and macular choroidal area using enhanced depth imaging optical coherence tomographyPLoS One2020154e0231214.

8 

N Akyol A Kalkisim A Turk M Kola HI Imamoglu Evaluation of the effects on choroidal thickness of bimatoprost 0.03% versus a brinzolamide 1.0%/timolol maleate 0.5% fixed combinationCutan Ocul Toxicol2017364397403

9 

S Bayraktar Z Cebeci B Izgi K Kasali The Effect of Glaucoma Medication on Choroidal Thickness Measured with Enhanced Depth-Imaging Optical Coherence Tomography. Med HypothesisDiscov Innov Ophthalmol J2019814451

10 

N Cardascia M Vetrugno T Trabucco F Cantatore C Sborgia Effects of travoprost eye drops on intraocular pressure and pulsatile ocular blood flow: a 180-day, randomized, double-masked comparison with latanoprost eye drops in patients with open-angle glaucomaCurr Ther Res2003647389400

11 

KS Lim CB Nau MM O'Byrne DO Hodge CB Toris JW McLaren Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover studyOphthalmology200811557905

12 

P Denis D Covert A Realini Travoprost in the management of open-angle glaucoma and ocular hypertensionClin Ophthalmol Auckl NZ2007111124

13 

OG Koz A Ozsoy A Yarangumeli SK Kose G Kural Comparison of the effects of travoprost, latanoprost and bimatoprost on ocular circulation: a 6-month clinical trialActa Ophthalmol Scand200785883843

14 

M Entezari S Karimi A Ramezani H Nikkhah Y Fekri B Kheiri Choroidal thickness in healthy subjectsJ Ophthalmic Vis Res20181313943

15 

YJ Song YK Kim JW Jeoung KH Park Assessment of Open-Angle Glaucoma Peripapillary and Macular Choroidal Thickness Using Swept-Source Optical Coherence Tomography (SS-OCT)PLoS One2016116e0157333

16 

AJ Lee P McCluskey Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertensionClin Ophthalmol2010474164

17 

JE Grunwald Effect of topical timolol on the human retinal circulationInvest Ophthalmol Vis Sci1986271217139

18 

OA Raslan MA Zaki TF Eliwa IGT Helal Peripapillary and Macular Choroidal Thickness in GlaucomaMed J Cairo Univ202088612971305

19 

L Vijaya R George M Baskaran H Arvind P Raju SV Ramesh Prevalence of primary open-angle glaucoma in an urban south Indian population and comparison with a rural population. The Chennai Glaucoma StudyOphthalmology2008115464854

20 

Z Duru C Özsaygılı DM Ulusoy AA Demirtaş Does using topical latanoprost affect subfoveal choroidal thickness?Cutan Ocul Toxicol20193843704

21 

N Sahinoglu-Keskek H Canan Effect of Latanoprost on Choroidal ThicknessJ Glaucoma20182776357

22 

O Artunay A Senel A Sengul R Rasier H Bahcecioglu Central Serous Chorioretinopathy Associated with Topical Latanoprost TherapyOcul Immunol Inflamm20111964535



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Article type

Original Article


Article page

497-501


Authors Details

Gajashree S*, Neha Chawla Guliani, Sangeeta Abrol, Rajshekhar Vemparala, Brahm Prakash Guliani


Article History

Received : 26-12-2023

Accepted : 08-04-2024


Article Metrics


View Article As

 


Downlaod Files